Gastrointestinal Pathobiology Research Group, Department of Surgery, Yale University School of Medicine, 310 Cedar Street, PO Box 208602, New Haven, CT 06520-8062, USA.
Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii. doi: 10.1016/j.ecl.2010.12.005.
In this article, updated analyses of the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) registry (1973-2007) are presented and compared with epidemiologic GEP-NET data from Europe and Asia. Several studies have demonstrated a steadily increasing incidence of GEP-NETs, and this escalation is still ongoing (SEER data 2004-2007). The common primary GEP-NET sites exhibit unique epidemiologic profiles with distinct patterns of incidence, age at diagnosis, stage, and survival. Overall, GEP-NET survival has improved over the past 3 decades, although the outcome for poorly differentiated tumors remains dismal.
本文呈现了美国国家癌症研究所监测、流行病学和结果（SEER）注册中心（1973-2007 年）的最新分析结果，并与来自欧洲和亚洲的胃肠胰神经内分泌肿瘤（GEP-NET）的流行病学数据进行了比较。多项研究表明 GEP-NET 的发病率呈稳步上升趋势，而且这种上升仍在持续（SEER 数据 2004-2007 年）。常见的胃肠道胰腺神经内分泌肿瘤的原发部位表现出独特的流行病学特征，具有不同的发病模式、诊断时的年龄、分期和生存情况。总的来说，过去 30 年来，胃肠胰神经内分泌肿瘤的生存率有所提高，尽管低分化肿瘤的预后仍然很差。
